A Non-interventional Post Authorisation Registry of Patients Treated With Pomalidomide for Relapsed and Refractory Multiple Myeloma Who Have Received at Least Two Prior Treatment Regimens, Including Both Lenalidomide and Bortezomib, and Have Demonstrated Disease Progression on the Last Therapy

Trial Profile

A Non-interventional Post Authorisation Registry of Patients Treated With Pomalidomide for Relapsed and Refractory Multiple Myeloma Who Have Received at Least Two Prior Treatment Regimens, Including Both Lenalidomide and Bortezomib, and Have Demonstrated Disease Progression on the Last Therapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs Pomalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 17 Jun 2018 Results of a real life analysis assessing long term disease control (n=56) in relapsed/refractory multiple myeloma patients treated with pomalidomide and dexamethasone, previously enrolled in an interventional (STRATUS, MM-010) or currently enrolled in an observational study (MM-015), presented at the 23rd Congress of the European Haematology Association.
    • 17 Jun 2018 Results (n=530) presented at the 23rd Congress of the European Haematology Association.
    • 30 Nov 2017 Planned number of patients changed from 700 to 750.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top